Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Geron Demonstrates hESC-derived cardiomyocytes improve heart function after myocardial infarction

Geron Demonstrates hESC-derived cardiomyocytes improve heart function after myocardial infarction

August 27, 2007

Geron Corporation (Nasdaq: GERN) today reported its scientists and collaborators have demonstrated that human embryonic stem cell (hESC)-derived cardiomyocytes improve heart function when transplanted after myocardial infarction.

Published online Aug. 26 in Nature Biotechnology, the landmark study is the first to document the potential clinical utility of regenerating damaged heart muscle by injecting hESC-derived cardiomyocytes directly into the site of the infarct. In addition, the research confirms the effectiveness of a scalable production system that enables Geron to manufacture the cardiomyocytes for use in ongoing large animal studies and, ultimately, testing in humans.




The study describes the feeder- and serum-free, scalable production of hESC-derived cardiomyocytes, their survival in the infarct zone of rats when transplanted four days after infarction, and echocardiographic and MRI evidence of significant improvement in cardiac structure and contractile function. Geron's scientists conducted the study in collaboration with Charles Murry, M.D., Ph.D., and Michael Laflamme, M.D., Ph.D., at the University of Washington.

"This is one of the most important publications on hESCs for Geron to date," said Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer. "Our cardiomyocytes are the first human cardiac cells shown to survive after injection into an infarcted ventricle and to produce significant improvement in heart function. hESCs are the only cell type shown definitively to form cardiomyocytes."

Approximately 5.2 million people in the United States suffer from heart failure, and approximately 865,000 people experience myocardial infarction each year. About 36% of this population progresses to heart failure within five years of a first infarction. More than one-third of all heart failure patients die within two years of diagnosis.

"We're developing our cardiomyocyte product, GRNCM1, to address the large unmet need in heart failure," Dr. Okarma added. "We expect GRNCM1 to be our second hESC-derived cell type to enter clinical development."

Production and Characterization of hESC-derived Cardiomyocytes

In the study, researchers produced human cardiomyocytes from hESCs using a sequential, directed differentiation protocol that did not rely on serum or feeder cells. The procedure was scalable and efficient, with each hESC producing approximately three human cardiomyocytes. After final enrichment, greater than 80% of the cells were cardiomyocytes. The hESC-derived cardiomyocytes displayed surface and intracellular markers, as well as electrophysiologic and pharmacologic properties consistent with human cardiomyocytes, the majority of which represented ventricular cardiomyocytes.

Engraftment Following Transplantation

To enable survival in the heart, the hESC-derived cardiomyocytes were suspended in a cocktail of survival factors that had been experimentally determined to dramatically enhance cell survival after injection into the infarcted ventricular wall. Four weeks later, tissue sections from the infarcted hearts were examined for the presence of the human cells. The vast majority of human cardiomyocytes were localized in the central region of the infarct, suggesting that the cells were capable of engraftment in the hostile environment of the infarct zone. Moreover, a portion of the cardiomyocytes was mitotic after injection, possibly enhancing their regenerative efficiency. The grafts also induced a brisk, host-derived angiogenic response: all the implants contained numerous capillaries lined with rat endothelial cells.

Safety

No teratomas, tumor masses, or aberrant structures were seen in any of the hearts receiving hESC-derived cardiomyocytes. A highly sensitive PCR assay was used to determine whether any hESC-derived cells had migrated to other non-cardiac organs. None were detected in brain, kidney, liver, lung or spleen, indicating the absence of migration of the injected cells from the heart.

Impact of Transplanted hESC-derived Cardiomyocytes on Cardiac Structure and Function

To assess the impact of injected cells on cardiac structure and function, all animals received echocardiography at baseline (two days after infarction but two days prior to cell injection) and at four weeks post cardiomyocyte implantation. All animals exhibited significant cardiac dysfunction two days post infarct. On average, left-ventricular end diastolic and systolic diameters increased by 10% and 42%, respectively, and fractional shortening decreased by 40% compared to uninfarcted controls.

Four days after infarction, animals were injected with 10 million hESC-derived cardiomyocytes suspended in the survival cocktail. Animals injected with either the survival cocktail alone, serum-free media without cells, or equivalent numbers of non-cardiac hESC-derived cells suspended in the survival cocktail served as control groups.

Echocardiography performed four weeks after cell implantation showed attenuation of left-ventricular end-diastolic and end-systolic diameters in animals receiving cardiomyocytes versus all three control groups. In addition, fractional shortening was significantly improved (0.01) in animals that received cardiomyocytes compared to all three control groups. MRI analysis showed improved left-ventricular ejection fraction (p=0.05) in the cardiomyocyte-treated rats compared to controls, as well as a 2.5-fold increase in systolic wall thickening in the infarct zone relative to controls (0.01).

Significance

This study is the first to document the potential clinical utility of regenerating damaged heart muscle by injecting hESC-derived cardiomyocytes directly into the infarct zone of the heart. The survival cocktail administered with the cells enables their long-term survival in the infarcted muscle. The injected cells stimulate endogenous blood vessel formation, possibly contributing to both cell survival and improved contractile function. The scalable production system allows for production runs at sufficient scale for large animal studies (ongoing) as well as for ultimate testing in humans.

Russo Partners, LLC



Related Myocardial Infarction Current Events and Myocardial Infarction News Articles Myocardial Infarction Current Events and Myocardial Infarction News RSS Myocardial Infarction Current Events and Myocardial Infarction News RSS
An ESC statement on gender differences in medical care and survival after myocardial infarction
A paper published online by the journal Circulation on 8 December 2008 concluded that, while men and women have a similar in-hospital death rate following acute myocardial infarction, women with STEMI had an adjusted mortality rate almost twice as high as men (10.2% versus 5.5%).

Patients with severe psoriasis need evaluation of heart disease risk
According to new recommendations in the December 10 issue of The American Journal of Cardiology (AJC), published by Elsevier, new research is called for and patients with severe forms of the skin disease psoriasis should receive evaluation and possible treatment to reduce their risk of coronary artery disease (CAD).

Research highlights new approaches to prevent blood clots
Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured.

Children's Hospital scientists achieve repair of injured heart muscle in lab tests of stem cells
Researchers at Children's Hospital of Pittsburgh of UPMC have been able to effectively repair damaged heart muscle in an animal model using a novel population of stem cells they discovered that is derived from human skeletal muscle tissue.

Vitamin C lowers levels of heart disease biomarker, finds study, adds to debate of health benefits
A new study led by researchers at the University of California, Berkeley, adds to the evidence that vitamin C supplements can lower concentrations of C-reactive protein (CRP), a central biomarker of inflammation that has been shown to be a powerful predictor of heart disease and diabetes.

Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes
Low-dose aspirin as primary prevention did not appear to significantly reduce the risk of a combined end point of coronary, cerebrovascular and peripheral vascular events in patients with type 2 diabetes, according to a new study in JAMA.

Risk of sudden cardiac death appears increased within 30 days of heart attack
The risk of sudden cardiac death following a heart attack has declined significantly in the past 30 years, although patients appear to be at elevated risk for sudden cardiac death for the first month after having a heart attack, after which time their risk decreases unless they develop heart failure, according to a study in the November 5 issue of JAMA.

Clock-shifts affect risk of heart attack
Adjusting the clocks to summer time on the last Sunday in March increases the risk of myocardial infarction in the following week. In return, putting the clocks back in the autumn reduces the risk, albeit to a lesser extent.

Developing depression after a heart attack increases one's risk of death or readmission
Science has found many links between depression and other serious medical illnesses, such as cancer, stroke, diabetes, and heart disease.

Study reveals embolic neuroprotection system reduces risk of cardiac events
Results of a study on the use of the FiberNet® Embolic Protection System in carotid artery stenting were reported today during the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).
More Myocardial Infarction Current Events and Myocardial Infarction News Articles
Myocardial Infarction: Pathophysiology for Nurses Video Series (Pathophysiology for Nurses Series)
by Blanchard-Loeb

Spot warning signs and symptoms of myocardial infarction (MI) and its life-threatening complications, and intervene quickly and expertly. You'll see exactly what's happening inside your patient's body and know exactly what it means for your nursing care before, during, and after an MI. In just 30 minutes, you'll learn how to: h respond swiftly and effectively to reduce the risk of sudden...



Myocardial Infarction: An Incredibly Easy! Miniguide

Pocket-sized guide to risk factors, pathophysiology, prevention, physical examination, diagnostic tests, drug therapy, complications, recovery, patient education, and more. Includes key concepts, quizzes, memory joggers, and color illustrations of pathophysiology. Two-tone format. For nurses. Trim size: 5.5 x 4.5 inches. Softcover. DNLM: Myocardial Infarction...



The 12 Lead ECG in ST Elevation Myocardial Infarction: A Practical Approcah for Clinicians
by Antonio Bayés de Luna, Miquel, MD Fiol-Sala, Elliot M., MD Antman

This guide to the proper use of the ECG in diagnosing acute myocardial infarction puts the combined experience of international authorities at your fingertips for immediate use. In The 12 Lead ECG in ST Elevation MI: A Practical Approach for Clinicians, Drs. Bayés de Luna, Fiol-Sala and Antman supply the practical, specific information you need to determine which patients with ACS are showing ST...



The 12-Lead ECG: In Acute Myocardial Infarction
by Tim Phalen

This book reflects the need of EMTs, paramedics, emergency and flight nurses to utilize more sophisticated equipment to assess myocardial infarction, and reduce the damage it does to the heart. This is the first book to focus exclusively on 12-lead interpretation for the prehospital professional. Contents also include the effects of infarction location and coronary...



Reperfusion Therapy for Acute Myocardial Infarction (Fundamental and Clinical Cardiology)

Covering the latest clinical trials and guidelines, this source provides a comprehensive review of reperfusion therapy for ST-segment elevation myocardial infarction (STEMI). With an international team of contributors, this source addresses key developments that will reduce logistical barriers, improve times-to-treatment, and ensure that appropriate medications are administered in patient...

Myocardial Infarction: Electrocardiographic Differential Diagnosis
by Ary Louis Goldberger



The Electrocardiogram in Acute Myocardial Infarction

The descriptive features associated with myocardial infarction are well known. However, now that interventional treatments such as acute thrombolysis and angioplasty have become so successful in limiting evolving myocardial infarction, new roles for the electrocardiogram in acute infarction are being explored. This timely text examines them all. They are:- detecting patency of the infarct-related...

Potassium in Cardiovascular and Renal Medicine: Arrhythmias, Myocardial Infarction, and Hypertension (Kidney Disease Series, Vol 6)
by Paul K. Whelton, Andrew Whelton



The ECG in Acute Myocardial Infarction and Unstable Angina (Developments in Cardiovascular Medicine)
by H.J.J Wellens, Anton M. Gorgels, P. Doevendans

This volume, written by the leaders in the field, will provide a practical and comprehensive overview of the electrocardiogram (ECG). The ECG remains the most accessible and inexpensive diagnostic tool to evaluate the patient presenting with symptoms suggestive of acute myocardial ischemia. The ECG in Acute Myocardial Infarction and Unstable Angina, written by Drs. Hein Wellens, Anton...



Acute Myocardial Infarction
by Bernard J. Gersh, Shahbudin H. Rahimtoola

Mayo Foundation, Rochester, MN. Comprehensive, detailed overview of acute myocardial infarction, for cardiologists. Halftone illustrations, some color. 53 contributors, 47 U.S. DNLM: Myocardial Infarction -...

© 2009 BrightSurf.com